A Registry Study of Biomarkers in Mitral Valve Disease (BIOMS-MVD)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

5000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2016-04-01

Study Completion Date

2025-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The registry study aims to discover the prognostic value of bio-markers in mitral valve disease

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Impact of Persistent Microvascular Obstruction by Cardiac Magnetic Resonance on Prognosis for ST-segment Elevation Myocardial Infarction

NCT06759532

ST Elevation (STEMI) Myocardial Infarction

COMPLETED

Multimodality Evaluation of Left Ventricular Remodeling In Mitral Regurgitation: A Pilot Study

NCT06770062

Left Ventricular Systolic Dysfunction

RECRUITING

A Prospective Multicenter Clinical Study on the Long-term Prognosis of Patients With ST-segment Elevation Myocardial Infarction Using Cardiac Magnetic Resonance Imaging.

NCT07057492

ST-segment Elevation Myocardial Infarction (STEMI)

COMPLETED

Cardiac Magnetic Resonance for Risk Stratification in Dilated Cardiomyopathy

NCT04990297

Dilated Cardiomyopathy Single-center Study

RECRUITING

Registry of Multicenter Brain-Heart Comorbidity in China

NCT05961748

Ischemic Heart Disease Cardiac Arrest Atrial Fibrillation +10 more

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The purpose of this study is to investigate the prognostic value of biomarkers in mitral valve disease.Patients with confirmed diagnosis of mitral valve disease are enrolled.The primary outcome is all-cause mortality based on the death certificates. The secondary outcome is readmission for heart failure and all-cause mortality/readmission for heart failure according to the patients' medical records.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cardiovascular Diseases

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients clinically diagnosed with mitral valve disease in Beijing Anzhen Hospital from April 2016 to December 2019
* The operator performs more than 25 mitral valve operations per year / the operator unit has surgeons who complete 50 operations per year

Exclusion Criteria

* Age ≤ 18 years
* Failure to obtain medical records and ultrasound data
* Refuse follow-up

Minimum Eligible Age

18 Years

Maximum Eligible Age

100 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Jie Du

Role: STUDY_DIRECTOR

The Key Laboratory of Remodeling-Related Cardiovascular Disease, Ministry of Education, Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart,Lung and Blood Vessel Diseases